t
On 7 August 2025, Vulpes Testudo Fund, a fund closely associated with Scancell Holdings plc Non-Executive Director Martin Diggle, purchased 102,236 ordinary shares in Scancell Holdings plc at a price of 10.85 pence per share. Following this purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 140,387,037 ordinary shares, representing 13.53% of the company.
| Date | 8 Aug 2025 |
| Time | 12:31:39 |
| Category | Director/PDMR dealings |
| ID | 6455U |
8 August 2025
Scancell Holdings plc
("Scancell" or the "Company")
Director Dealing
Scancell Holdings plc (AIM: SCLP), the developer of Immunobody® and Moditope® active immunotherapies to treat cancer, announces that Vulpes Testudo Fund, a fund closely associated with Martin Diggle, Non-Executive Director, has purchased 102,236 ordinary shares of 0.1p each ('Ordinary Shares') in the Company on 7 August 2025 at a price of 10.85 pence per share. Following the purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 140,387,037 ordinary shares representing 13.53% of the company.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Vulpes Testudo Fund |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Fund closely associated with Martin Diggle, Non-Executive Director |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Scancell Holdings plc |
|
b) |
LEI |
2138008RXEG856SNP666 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.1 pence each |
|
b) |
Identification Code |
GB00B63D3314 |
|
c) |
Nature of the transaction |
Purchase of Ordinary Shares |
|
|
|
|
|
d) |
Price(s) and volume(s) |
10.85 pence and 102,236 |
|
e) |
Aggregated information - Aggregated volume - Price |
102,236 Ordinary Shares 10.85 pence per Ordinary Share |
|
f) |
Date of the transaction (s) |
7 August 2025 |
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
-ENDS-
Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage biotechnology company developing targeted off-the-shelf active immunotherapies, to generate safe and long-lasting tumor-specific immunity for a cancer-free future. iSCIB1/iSCIB1+, the lead product from their DNA Immunobody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope® platform, is being investigated in a Phase 2 study in a broad range of solid tumors. In addition, Scancell's wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumor specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.
For more information please contact:
|
|
|
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Phil L'Huillier, CEO |
|
|
Sath Nirmalananthan, CFO |
|
|
|
|
|
Panmure Liberum (Nominated Adviser and Joint Broker) |
+44 (0) 20 7886 2500 |
|
Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) |
|
|
|
|
|
WG Partners LLP (Joint Broker) David Wilson, Claes Spang |
+44 (0) 20 3705 9330
|
|
|
|
|
Investor and media relations Mary-Ann Chang |
+44 (0) 20 7483 284853 |
|
|
|